Home > Insider Trading > Filing (0001209191-22-062666)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1786255	Icosavax Inc.	ICVX	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1873839	K. Adam Simpson	C/O Icosavax, Inc. 1930 Boren Ave., Suite 1000 Seattle WA 98101	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-12-21	66,764	$8.96	225,105	No	4	S	Direct
Common Stock	Acquisiton	2022-12-23	14,369	$0.84	239,474	No	4	M	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	M	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2022-12-23	14,369	$0.00	14,369	$0.84

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
33,527		2030-05-10	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	531,576	Indirect	By family trust
Common Stock	129,032	Indirect	By family trust
Common Stock	129,032	Indirect	By family trust

Footnotes

Represents the sale by the Reporting Person, pursuant to a Rule 10b5-1 trading plan, of a portion of the shares of the Issuer purchased by the Reporting Person via exercise of incentive stock options during 2022. These shares are being sold by the Reporting Person prior to the end of 2022 in order to trigger a disqualifying disposition of such shares and to eliminate the alternative minimum tax that would otherwise arise as a result of the Reporting Person's exercise of such incentive stock options during 2022, with the remainder of the purchased shares continued to be held by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.54 to $9.41. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
25% of the shares subject to the option vested on 2/21/2021, and 1/48th of the shares subject to the option vest monthly thereafter.